# Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

> **NCT02420652** · PHASE2 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 27 (actual)

## Conditions studied

- Recurrent Prostate Carcinoma
- Stage I Prostate Cancer
- Stage IIA Prostate Cancer
- Stage IIB Prostate Cancer
- Stage III Prostate Cancer

## Interventions

- **DRUG:** Aspirin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Metformin Hydrochloride
- **OTHER:** Placebo
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02420652
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06-23
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420652, "Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02420652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*